Literature DB >> 7790089

Antibody response that protects against disseminated candidiasis.

Y Han1, J E Cutler.   

Abstract

We previously showed that surface mannans of Candida albicans function as adhesins during yeast cell attachment to mouse splenic marginal zone macrophages. The mannan adhesin fraction was encapsulated into liposomes and used to vaccinate mice over a 5- to 6-week period. Circulating agglutinins specific for the fraction correlated with increased resistance to disseminated candidiasis. Antiserum from vaccinated animals protected naive BALB/cByJ mice against C. albicans serotype A and B strains and Candida tropicalis. Antiserum also protected SCID mice against disseminated disease. The serum protective ability was stable at 56 degrees C, but this ability was adsorbed by C. albicans cells. The antiserum was divided into three fractions after separation by high-performance liquid chromatography. One fraction contained all of the agglutinin activity and transferred resistance to naive mice. A second fraction also transferred resistance. Two monoclonal antibodies (MAbs) specific for candidal surface determinants were obtained. MAb B6.1 is specific for a mannan epitope in the adhesin fraction, and MAb B6 is specific for a different epitope in the fraction. Both MAbs are immunoglobulin M, and both strongly agglutinate candidal cells, but only MAb B6.1 protected both normal and SCID mice against disseminated candidiasis. In one experiment, 10 normal mice were given MAb B6.1 and challenged with yeast cells. Six mice survived the 67-day observation period; 4 of the survivors were cured as evidenced by the lack of CFU in the kidney and spleen. Our studies show that antibodies against certain cell surface antigens of C. albicans help the host resist disseminated candidiasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790089      PMCID: PMC173363          DOI: 10.1128/iai.63.7.2714-2719.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Active immunization of mice against Candida albicans.

Authors:  S MOURAD; L FRIEDMAN
Journal:  Proc Soc Exp Biol Med       Date:  1961-03

2.  Passive immunization of mice against Candida albicans.

Authors:  S Mourad; L Friedman
Journal:  Sabouraudia       Date:  1968-02

3.  Variability in expression of cell surface antigens of Candida albicans during morphogenesis.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

4.  Experimental murine candidiasis: pathological and immune responses in T-lymphocyte-depleted mice.

Authors:  D K Giger; J E Domer; S A Moser; J T McQuitty
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

5.  Role of antibody in defence against murine candidosis.

Authors:  U Banerjee; L N Mohapatra; R Kumar
Journal:  Indian J Med Res       Date:  1984-06       Impact factor: 2.375

6.  Isolation and partial characterization of an adhesin from Candida albicans.

Authors:  I A Critchley; L J Douglas
Journal:  J Gen Microbiol       Date:  1987-03

7.  Immunologic responses to Candida albicans. III. Effects of passive transfer of lymphoid cells or serum on murine candidiasis.

Authors:  N N Pearsall; B L Adams; R Bunni
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

8.  Ultrastructural and biochemical studies of two dynamically expressed cell surface determinants on Candida albicans.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

9.  Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody.

Authors:  D L Brawner; J E Cutler
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

10.  A serum-dependent defect of neutrophil function in chronic mucocutaneous candidiasis.

Authors:  S M Walker; S J Urbaniak
Journal:  J Clin Pathol       Date:  1980-04       Impact factor: 3.411

View more
  90 in total

1.  Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment.

Authors:  Melanie Wellington; Joseph M Bliss; Constantine G Haidaris
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 2.  Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.

Authors:  Arturo Casadevall
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 3.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

4.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

5.  Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans.

Authors:  M J Gomez; B Maras; A Barca; R La Valle; D Barra; A Cassone
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

6.  Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  Biological activities of naturally occurring antibodies reactive with Candida albicans mannan.

Authors:  Thomas R Kozel; Randall S MacGill; Ann Percival; Qing Zhou
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  CD86 (B7-2), but not CD80 (B7-1), expression in the epidermis of transgenic mice enhances the immunogenicity of primary cutaneous Candida albicans infections.

Authors:  A A Gaspari; R Burns; A Nasir; D Ramirez; R K Barth; C G Haidaris
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 9.  Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges.

Authors:  James Masuoka
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Contrasting roles of mannan-specific monoclonal immunoglobulin M antibodies in the activation of classical and alternative pathways by Candida albicans.

Authors:  M X Zhang; J E Cutler; Y Han; T R Kozel
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.